DK2457581T3 - Sammensætning omfattende CNP eller BNP for et udvendigt præparat til hud til behandling af dermatitis - Google Patents

Sammensætning omfattende CNP eller BNP for et udvendigt præparat til hud til behandling af dermatitis

Info

Publication number
DK2457581T3
DK2457581T3 DK10802352.4T DK10802352T DK2457581T3 DK 2457581 T3 DK2457581 T3 DK 2457581T3 DK 10802352 T DK10802352 T DK 10802352T DK 2457581 T3 DK2457581 T3 DK 2457581T3
Authority
DK
Denmark
Prior art keywords
cnp
gdp
dermatitis
treatment
composition
Prior art date
Application number
DK10802352.4T
Other languages
Danish (da)
English (en)
Inventor
Kyoko Endo
Original Assignee
Igisu Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igisu Co Ltd filed Critical Igisu Co Ltd
Application granted granted Critical
Publication of DK2457581T3 publication Critical patent/DK2457581T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
DK10802352.4T 2009-07-23 2010-07-23 Sammensætning omfattende CNP eller BNP for et udvendigt præparat til hud til behandling af dermatitis DK2457581T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009172589 2009-07-23
JP2010134600 2010-06-11
PCT/JP2010/062459 WO2011010732A1 (ja) 2009-07-23 2010-07-23 皮膚外用剤組成物

Publications (1)

Publication Number Publication Date
DK2457581T3 true DK2457581T3 (da) 2014-03-31

Family

ID=43499204

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10802352.4T DK2457581T3 (da) 2009-07-23 2010-07-23 Sammensætning omfattende CNP eller BNP for et udvendigt præparat til hud til behandling af dermatitis

Country Status (14)

Country Link
US (4) US20120208756A1 (cg-RX-API-DMAC7.html)
EP (1) EP2457581B1 (cg-RX-API-DMAC7.html)
JP (5) JP4834190B2 (cg-RX-API-DMAC7.html)
KR (2) KR101533695B1 (cg-RX-API-DMAC7.html)
CN (4) CN105999230B (cg-RX-API-DMAC7.html)
AU (1) AU2010274293B9 (cg-RX-API-DMAC7.html)
BR (1) BR112012001491B1 (cg-RX-API-DMAC7.html)
CA (1) CA2768810C (cg-RX-API-DMAC7.html)
DK (1) DK2457581T3 (cg-RX-API-DMAC7.html)
ES (1) ES2456502T3 (cg-RX-API-DMAC7.html)
MX (1) MX2012001024A (cg-RX-API-DMAC7.html)
NZ (1) NZ597797A (cg-RX-API-DMAC7.html)
RU (2) RU2572694C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011010732A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105999230B (zh) * 2009-07-23 2022-06-24 Igisu株式会社 皮肤外用剂组合物
EP2666475B1 (en) 2011-01-21 2017-08-16 Igisu Co., Ltd. Therapeutic agent for alopecia
ES2488740B1 (es) * 2012-10-10 2015-06-11 J. Álvaro GALIANO RAMOS Formulación cosmética y dermatologica para el alivio del prurito
CN104367925A (zh) * 2014-11-07 2015-02-25 济南高达信息技术有限公司 一种治疗红皮病的中药洗剂及其制备方法
AU2016272282A1 (en) 2015-05-29 2018-01-25 Igisu Co., Ltd. Cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
RU2018102137A (ru) 2015-06-19 2019-07-19 Глобал Хелс Солюшенз, Ллк. Системы доставки на основе вазелина и для активных ингредиентов
CA2994091A1 (en) * 2015-07-31 2017-02-09 Igisu Co., Ltd. A cnp cyclic peptide and a medicament, external preparation and cosmetic comprising the cyclic peptide
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
BR112018072467A2 (pt) * 2016-05-05 2019-02-19 Aquestive Therapeutics, Inc. composições farmacêuticas com permeação aumentada
US20200030411A1 (en) * 2016-09-21 2020-01-30 Agency For Science, Technology And Research Methods and Compositions for Inhibiting Skin Inflammation and Determining Cancer Susceptibility
JP7125862B2 (ja) * 2018-05-29 2022-08-25 小林製薬株式会社 外用組成物
JP2019214520A (ja) * 2018-06-12 2019-12-19 花王株式会社 角層剥離改善剤
CN110302194B (zh) * 2019-07-23 2023-01-31 广州市皮肤病防治所(广州市性病防治监测中心) 一种具有抗炎和皮肤屏障保护作用的桉叶素联合糖皮质激素的复方制剂
US11419917B2 (en) * 2020-04-07 2022-08-23 Drora Shevy Treatment for SARS-CoV-2 and other coronaviruses
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
JP7466939B2 (ja) * 2022-08-31 2024-04-15 東洋ビューティ株式会社 Ｏ／ｄ相組成物及び水中油型乳化組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
JPH05207891A (ja) 1991-03-08 1993-08-20 Shionogi & Co Ltd 脳性ナトリウム利尿ペプチドの製造方法
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US5965533A (en) 1997-05-23 1999-10-12 Baxter International Inc. Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
KR100691545B1 (ko) 1998-09-28 2007-03-09 산텐 세이야꾸 가부시키가이샤 나트륨 이뇨 펩티드를 유효 성분으로하는 누액 분비 촉진또는 각결막 장해 치료용 점안제
JP3799465B2 (ja) 1998-09-28 2006-07-19 参天製薬株式会社 ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
JP3676707B2 (ja) * 2001-07-18 2005-07-27 三菱電機株式会社 車両用交流発電機の固定子およびその製造方法
WO2004022003A2 (en) 2002-09-06 2004-03-18 University Of South Florida Materials and methods for treatment of allergic diseases
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
CN100558398C (zh) 2002-11-26 2009-11-11 拜奥康有限公司 修饰的钠尿化合物、缀合物及其应用
US20040161435A1 (en) * 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
CN1816353B (zh) * 2003-06-13 2010-05-05 阿斯比奥制药株式会社 用于预防或治疗Th1型免疫疾病的药物组合物
CN101208353B (zh) * 2003-06-20 2011-12-14 梅约医学教育与研究基金会 脑利尿钠肽的同种型
JP2007525213A (ja) 2004-01-27 2007-09-06 コンピュゲン ユーエスエイ，インク． 新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法
CA2554599A1 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
JP4972403B2 (ja) 2004-03-31 2012-07-11 一和 中尾 身長増加用組成物
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
JP2008509746A (ja) 2004-08-11 2008-04-03 アルザ・コーポレーシヨン ナトリウム利尿ペプチドを経皮送達する器具および方法
EP1810716A1 (de) * 2005-12-23 2007-07-25 Deutsches Zentrum für Luft- und Raumfahrt e.V. Verfahren zur Bräunung der Haut
DE102004048576A1 (de) * 2004-10-04 2006-04-13 Deutsches Zentrum für Luft- und Raumfahrt e.V. Methode zur Bräunung der Haut
BRPI0716416A2 (pt) 2006-08-08 2016-10-11 Mayo Foundation polipeptídeo substancialmente puro entre 37 e 47 besíduos de aminoácido de comprimento, ácido nucléico isolado, vetor: célula hospedeira e composição farmacêutica
WO2008032450A1 (fr) 2006-09-15 2008-03-20 Kyoto University Agent prophylactique et/ou thérapeutique pour une stéatose hépatique
US20120034183A1 (en) 2006-12-19 2012-02-09 Michael Cohen Compositions and methods for growing embryonic stem cells
JP5010913B2 (ja) * 2006-12-31 2012-08-29 寿子 小出 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2010168283A (ja) 2007-04-24 2010-08-05 Yamaguchi Univ ナトリウム利尿ペプチドを有効成分とする肝硬変・前癌病変の抑制剤
JP5207316B2 (ja) 2007-05-10 2013-06-12 国立大学法人名古屋大学 腹膜線維化抑制用医薬組成物
US20100204090A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009033799A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8377884B2 (en) * 2007-11-21 2013-02-19 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptides
US8741842B2 (en) 2008-07-02 2014-06-03 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides with unique pharmacologic profiles
WO2010048308A2 (en) * 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
US8150603B2 (en) 2008-11-26 2012-04-03 Caterpillar Inc. Engine control system having fuel-based timing
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
KR102033680B1 (ko) 2009-05-20 2019-10-18 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
CN105999230B (zh) 2009-07-23 2022-06-24 Igisu株式会社 皮肤外用剂组合物
JP2011024973A (ja) * 2009-07-24 2011-02-10 Mitsumasa Maeda 電子ペーパー付き便蓋
RU2502519C2 (ru) 2009-08-27 2013-12-27 Кёко ЭНДО Терапевтическое средство для лечения ринита
ITPG20090061A1 (it) 2009-11-27 2011-05-28 Andrea Marcantonini Impianto mobile per la produzione di calcestruzzo
EP2666475B1 (en) 2011-01-21 2017-08-16 Igisu Co., Ltd. Therapeutic agent for alopecia

Also Published As

Publication number Publication date
RU2572694C2 (ru) 2016-01-20
AU2010274293B9 (en) 2013-08-29
KR101226165B1 (ko) 2013-01-24
JP2017061556A (ja) 2017-03-30
CN102470163A (zh) 2012-05-23
CN102470163B (zh) 2016-06-15
MX2012001024A (es) 2012-04-11
JP2016006058A (ja) 2016-01-14
JP2012017316A (ja) 2012-01-26
EP2457581B1 (en) 2014-01-08
NZ597797A (en) 2013-11-29
CA2768810A1 (en) 2011-01-27
JP5778440B2 (ja) 2015-09-16
RU2012103653A (ru) 2013-08-27
KR101533695B1 (ko) 2015-07-06
JP6337071B2 (ja) 2018-06-06
US20140072520A1 (en) 2014-03-13
US9968654B2 (en) 2018-05-15
CN110339346B (zh) 2023-06-27
AU2010274293B2 (en) 2013-06-06
CN110339346A (zh) 2019-10-18
EP2457581A1 (en) 2012-05-30
US9358269B2 (en) 2016-06-07
CN104189893B (zh) 2018-10-23
ES2456502T3 (es) 2014-04-22
JP2018135381A (ja) 2018-08-30
CN105999230B (zh) 2022-06-24
CN104189893A (zh) 2014-12-10
US20120208756A1 (en) 2012-08-16
US20160250293A1 (en) 2016-09-01
CN105999230A (zh) 2016-10-12
RU2015150099A (ru) 2017-07-27
JPWO2011010732A1 (ja) 2013-01-07
BR112012001491B1 (pt) 2022-03-15
BR112012001491A2 (pt) 2020-01-28
KR20120049169A (ko) 2012-05-16
US10946072B2 (en) 2021-03-16
JP4834190B2 (ja) 2011-12-14
US20180099028A1 (en) 2018-04-12
CA2768810C (en) 2014-05-20
RU2015150099A3 (cg-RX-API-DMAC7.html) 2019-07-17
HK1171193A1 (en) 2013-03-22
KR20120130273A (ko) 2012-11-29
WO2011010732A1 (ja) 2011-01-27
AU2010274293B8 (en) 2013-07-04
JP6055518B2 (ja) 2016-12-27
AU2010274293A1 (en) 2012-02-23
EP2457581A4 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
DK2457581T3 (da) Sammensætning omfattende CNP eller BNP for et udvendigt præparat til hud til behandling af dermatitis
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK2819602T3 (da) Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
ZA201403795B (en) Formulations for the treatment of diabetes
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
DK2459553T3 (da) Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme
BRPI0907950A2 (pt) Tratamento de hiperglicemia com 25-hidroxivitamina d3
DK2588620T3 (da) Fremgangsmåde til fremstilling af butanol eller acetone
DK2839004T3 (da) Fremgangsmåde til at behandle diabetes og/eller fremme overlevelse af langerhanske øer efter transplantation
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2522342T3 (da) Topisk formulering til behandling af hyperkeratonisk hud
DK2470202T3 (da) Clostridium-neurotoksiner til anvendelse i behandling af præmatur ejakulation
DK2407151T3 (da) Sammensætning til behandling af hud- og/eller neglelæsioner
BR112013033732A2 (pt) composição de revestimento de fibra de vidro
EP2494966A4 (en) STABLE COMPOSITION OF RASAGILINE
DK2646011T3 (da) Fremgangsmåder til reduktion af overspisning eller tvangsspisning
DK3446565T3 (da) Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
EP2507309A4 (en) NETWORKING RESOURCES
DK2462108T3 (da) Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider
DOP2012000313A (es) Cristal de compuesto de amida
DK2705847T3 (da) Sammensætning til behandling af psoriasis
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi